Table 2.
Clinical information, efficacy evaluation, and COL6A1 expression of the 58 BC patients treated with Tislelizumab in our cohort.
| Clinical features | Total:58（%） | COL6A1 expression |
P-value | ||
|---|---|---|---|---|---|
| low | high | ||||
| Age | ＜60 | 15(25.86%) | 5 | 10 | |
| ≥60 | 43(74.13%) | 8 | 35 | - | |
| Gender | Male | 39(67.24%) | 8 | 31 | |
| Female | 19(32.76%) | 5 | 14 | - | |
| T | T1 | 0(0%) | 0 | 0 | |
| T2 | 7(12.07%) | 0 | 7 | ||
| T3 | 30(51.72%) | 9 | 21 | ||
| T4 | 15(25.86%) | 3 | 12 | ||
| Tx | 6(10.34%) | 1 | 5 | - | |
| N | N0 | 7(12.07%) | 0 | 7 | |
| N1 | 2(3.45%) | 0 | 2 | ||
| N2 | 21(36.21%) | 6 | 15 | ||
| N3 | 5(8.62%) | 2 | 3 | ||
| Nx | 23(39.66%) | 5 | 18 | - | |
| M | M0 | 0(0%) | 0 | 0 | |
| M1 | 55(94.83%) | 11 | 44 | ||
| Mx | 3(5.17%) | 2 | 1 | - | |
| Efficacy | CR | 2(3.45%) | 1 | 1 | |
| PR | 14(24.14%) | 6 | 8 | ||
| SD | 29(50.00%) | 4 | 25 | ||
| PD | 13(22.41%) | 2 | 11 | 0.04852* | |
Note: *: Wilcoxon rank-sum test between COL6A1 high- and low- expression groups(z = −1.973).